Background and Purpose—Edoxaban is a direct oral factor Xa inhibitor with proven efficacy
and safety among patients with atrial fibrillation. Concerns have been raised about an …

Background: Edoxaban, an oral factor Xa inhibitor with 50% renal clearance, was
noninferior to well-managed warfarin for stroke or systemic embolism (S/SE) prevention and …

Background To compare the efficacy and safety of edoxaban vs warfarin in high-risk
subgroups. Methods ENGAGE AF-TIMI 48 was a multicenter randomized, double-blind …

Background Oral anticoagulation therapy with warfarin or direct oral anticoagulants
(DOACs) is the mainstay for stroke prevention in patients with non‐valvular atrial fibrillation …

Objective To investigate the relative effect of warfarin versus non-vitamin K oral
anticoagulants (NOACs) in thrombotic and bleeding outcomes in subgroups of atrial …

Background It is unclear whether edoxaban shows better risk reduction of ischemic stroke,
bleeding, and all-cause mortality than warfarin in Asian patients with nonvalvular atrial …

Background: The short-term safety and plasma concentrations of edoxaban 15 mg once
daily in Japanese patients with non-valvular atrial fibrillation (NVAF) and severe renal …

Background The ENSURE-AF study (NCT 02072434) of anticoagulation for electrical
cardioversion in nonvalvular atrial fibrillation (NVAF) showed comparable low rates of …

Background Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have
substantially improved anticoagulation therapy for prevention of stroke and systemic …

Background In 21,105 patients with atrial fibrillation (AF), the ENGAGE AF–TIMI 48 trial
demonstrated that both higher dose (60 mg/30 mg dose reduced) and lower dose (30 mg/15 …